{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-037520","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.425553+00:00","generated_at":"2026-05-29T03:02:11.320823+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Reviva reports positive preliminary 1-year OLE data for brilaroxazine in schizophrenia","bullets":["435 patients enrolled in OLE; 113 completed 52 weeks; pooled PANSS total decreased 18.6 points (p≤0.0001).","Dose-dependent efficacy: PANSS total decreases of -15.2, -18.6, -20.8 for 15, 30, 50 mg doses.","Safety: 15.2% TRAE, mostly mild; no drug-related SAEs; discontinuation rate 35%, primarily withdrawal of consent (22%).","Long-term safety data from 100+ patients meets FDA NDA submission requirement; full OLE data expected Q1 2025.","Brilaroxazine generally well-tolerated with no single side effect >5%; no clinically meaningful movement disorder changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-037520","json":"https://secwatch.observer/filing/0001437749-24-037520.json","markdown":"https://secwatch.observer/filing/0001437749-24-037520.md","text":"https://secwatch.observer/filing/0001437749-24-037520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924037520/0001437749-24-037520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924037520/rvph20241215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:02:11.320823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}